

# Utilizing health economic modeling and translational action to demonstrate vaccine effectiveness for institutions combating AMR



**Elliot Lee, 2026, Econ/ORFE (undecided)**  
 One Health Trust, Bengaluru, Karnataka, India  
 Funded by CHW under Internships in Global Health (LENS)

\*DALYS = disability-adjusted life years  
 YLD (years lived with disability) + YLL (years of life lost)

## Introduction

- Antimicrobial resistance (AMR) refers to growing pathogen response against traditional treatments (i.e. antibiotics), rendering these treatments ineffective.
- 1.27 million deaths were attributable to bacterial AMR worldwide in 2019 (Murray et al., 2022)

## Objective

- Vaccinations have been proven effective in combating AMR by reducing prevalence of resistant pathogens and decreasing inappropriate antibiotic use (Micoli et al., 2021)
- Policymakers must be convinced that vaccination initiatives are worthwhile in reducing AMR burden

## Work Profile

- Contribute to policy briefs detailing the burden of AMR while synthesizing research studies that model vaccine effectiveness
- Run and tweak economic models that establish the cost-effectiveness of vaccines in combating AMR

## Reflection

### Part 1: Research Assistant (supervised by Dr. Giridara Gopal Parameswaran)

- Tweaked Markov models demonstrating the cost-benefit effectiveness of vaccines in reducing DALYS\* and infectious disease burden across all states and union territories in India excluding data-deficient zones that were noted
- Ran Monte Carlo-derived probabilistic sensitivity analyses for all available states and union territories to determine cost-benefit financial incentives for governments to pursue two different vaccination programs, then calculating and organizing obtained data
- Model inputs were inherently approached with uncertainty, and thus, represented using appropriate distributions in the analysis

### Part 2: Presentation (supervised by Dr. Erta Kalanxhi and Rishi Bhagawati)

#### Assisting GARP

- The Global Antibiotic Resistance Partnership (GARP) helps low- and middle-income countries develop policies to tackle AMR.
- Created presentations demonstrating the work of GARP for meetings with the following countries (Tanzania, Zimbabwe, India, Kenya, South Africa, Vietnam, Mozambique, Laos, Nigeria)
- Contributor to the following policy briefs on the value of vaccines to mitigate antimicrobial resistance (Pakistan, South Africa, Nepal, Uganda, Nigeria)
  - Wrote sections on infectious disease burden within these countries (for Pakistan, wrote sections including executive summary and the status quo of vaccination programs)

## Looking ahead | Conclusions

- Continue to work with Dr. Giri on creation of health economic models using R
- Presentations and policy briefs hopefully play a role in spurring effective vaccination programs in the nations who need them the most
- Internship taught some important basics regarding health economic modeling as well as the government-health interface

## Questions

- Examining potential impact that educational level and socioeconomic status have in stratifying access to appropriate AMR treatments, especially relating to information access regarding antibiotic misuse

## Acknowledgements

I would like to thank Dr. Ramanan Laxminarayan, Dr. Erta Kalanxhi, Rishi Bhagawati, Dr. Elloise du Toit, and Dr. Giridara Gopal Parameswaran for supervising me through this amazing internship experience, as well as the Center for Health and Wellbeing (CHW), LENS, and the entire team at One Health Trust for facilitating and supporting this internship. Thanks to their gracious support, I was able to have a genuine educational experience that I could not have received anywhere else.

